Downstaging of hepatocellular carcinoma prior to liver transplant: Is there a role for adjuvant sorafenib in locoregional therapy?

Parsia A. Vagefi, Ryutaro Hirose

Research output: Contribution to journalReview article

18 Scopus citations


Hepatocellular carcinoma (HCC) remains a common cause of mortality worldwide. Liver transplantation has emerged as the optimal treatment for cirrhotic patients with HCC; however, the shortage of donor organs leaves waitlisted patients at risk for disease progression beyond transplant criteria. Prevention of waitlist dropout has fueled investigation into a wide array of locoregional therapies for the management of HCC in candidates awaiting liver transplantation. We present a patient with HCC who underwent treatment with sorafenib, which resulted in a remarkable reduction in tumor burden to allow for liver transplant listing.

Original languageEnglish (US)
Pages (from-to)217-220
Number of pages4
JournalJournal of Gastrointestinal Cancer
Issue number4
StatePublished - Dec 1 2010



  • hepatocellular cancer
  • liver transplantation
  • locoregional therapy
  • sorafenib

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this